Received Apr 7, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Late 2nd dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 74-year-old male patient who received HAB (Twinrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 20-MAR-2026, the patient received the 2nd dose of Twinrix. On 20-MAR-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd dose). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-MAR-2026 The pharmacist called to inform that a couple of patients are doing the accelerated schedule before going on a trip. According to reporter, both patients got the 1st dose of Twinrix on 11-MAR-2026, and the 2nd one on 20-MAR-2026. According to reporter, the patients were intending to receive the 3rd dose on 27-MAR-2026, though at the moment of the call they had not received it yet. According to reporter, they did not have the lot number of the product since it had been administered in another facility. No further details provided. The batch number was not provided upon follow- up with the reporter. This case US2026041507 was reported by same reporter.; Sender's Comments: US-GSK-US2026041507:SAME REPORTER